JP2025500826A - 慢性腎疾患を処置するためのアルドステロンシンターゼ阻害薬 - Google Patents

慢性腎疾患を処置するためのアルドステロンシンターゼ阻害薬 Download PDF

Info

Publication number
JP2025500826A
JP2025500826A JP2024534762A JP2024534762A JP2025500826A JP 2025500826 A JP2025500826 A JP 2025500826A JP 2024534762 A JP2024534762 A JP 2024534762A JP 2024534762 A JP2024534762 A JP 2024534762A JP 2025500826 A JP2025500826 A JP 2025500826A
Authority
JP
Japan
Prior art keywords
alkyl
compound
formula
ckd
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500826A5 (https=
Inventor
リサ ヴイ クローニン
シビレ ジェニー ハウスケ
ハートムット リュッテン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2025500826A publication Critical patent/JP2025500826A/ja
Publication of JP2025500826A5 publication Critical patent/JP2025500826A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024534762A 2021-12-14 2022-12-13 慢性腎疾患を処置するためのアルドステロンシンターゼ阻害薬 Pending JP2025500826A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289177P 2021-12-14 2021-12-14
US63/289,177 2021-12-14
PCT/US2022/052631 WO2023114170A1 (en) 2021-12-14 2022-12-13 Aldosterone synthase inhibitors for treating chronic kidney disease

Publications (2)

Publication Number Publication Date
JP2025500826A true JP2025500826A (ja) 2025-01-15
JP2025500826A5 JP2025500826A5 (https=) 2026-01-07

Family

ID=85151059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534762A Pending JP2025500826A (ja) 2021-12-14 2022-12-13 慢性腎疾患を処置するためのアルドステロンシンターゼ阻害薬

Country Status (12)

Country Link
US (2) US12263157B2 (https=)
EP (1) EP4447961A1 (https=)
JP (1) JP2025500826A (https=)
KR (1) KR20240122521A (https=)
CN (1) CN118401241A (https=)
AR (1) AR127948A1 (https=)
AU (1) AU2022415313A1 (https=)
CA (1) CA3236890A1 (https=)
CL (1) CL2024001470A1 (https=)
MX (1) MX2024007335A (https=)
TW (1) TW202339719A (https=)
WO (1) WO2023114170A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019546A1 (en) * 2023-07-17 2025-01-23 Mineralys Therapeutics, Inc. Methods of treating chronic kidney disease (ckd) or ckd and hypertension with lorundrostat, or a combination of lorundrostat and a sglt2 inhibitor
TW202525278A (zh) * 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法
US20250255851A1 (en) * 2024-02-14 2025-08-14 Boehringer Ingelheim International Gmbh Solid forms of an aldosterone synthase inhibitor
WO2025190858A1 (en) * 2024-03-12 2025-09-18 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitor for treating heart failure

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008959A1 (fr) 1992-10-20 1994-04-28 Taisho Pharmaceutical Co., Ltd. Derive de prostaglandine
AU714033B2 (en) 1996-07-19 1999-12-16 Nissan Chemical Industries Ltd. Method for producing purified epoxy compound
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
ZA200500918B (en) 2002-10-15 2006-12-27 Otsuka Pharma Co Ltd 1-substituted 4-nitroimidazole compound and process for producing the same
CA2494710C (en) 2002-10-15 2011-05-03 Otsuka Pharmaceutical Co., Ltd. 1-substituted-4-nitroimidazole compound and method for preparing the same
EP1996588A4 (en) 2006-03-03 2011-10-05 Torrent Pharmaceuticals Ltd NEW DUAL ACTION RECEPTOR (DARA) ANTAGONISTS OF ATI AND ETA RECEPTORS
EP2001866A2 (en) 2006-03-29 2008-12-17 Novartis AG Organic compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
JP2007297305A (ja) 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
CA2660701A1 (en) 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010016987A1 (en) 2008-08-05 2010-02-11 Dow Global Technologies Inc. Production of solid epoxy resin
US20110172217A1 (en) 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
TW201026688A (en) 2008-10-07 2010-07-16 Schering Corp Benzodioxan analogues as alpha2C adrenergic receptor modulators
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
CA2761009A1 (en) 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
BR112012002214B1 (pt) 2009-07-31 2022-01-25 Global Alliance For Tb Drug Development Análogos de nitroimidazooxazina e nitroimidazooxazol, seus usos e composição farmacêutica
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
HRP20192323T1 (hr) 2011-09-15 2020-03-20 F. Hoffmann - La Roche Ag Novi derivati dihidrokinolin-2-ona
US9353081B2 (en) 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
AR088989A1 (es) 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
HRP20171996T1 (hr) 2012-04-17 2018-02-09 F. Hoffmann - La Roche Ag Novi derivati fenil-tetrahidroizokinolina
KR102096927B1 (ko) 2012-09-04 2020-04-06 삼성전자주식회사 제어 채널 엘리먼트들에 대한 어그리게이션 레벨들 개수 조정 장치 및 방법
CA2886117C (en) 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Indoline compounds and their use as aldosterone synthase inhibitors
US8912341B2 (en) 2013-01-16 2014-12-16 Northwestern University Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014168861A2 (en) 2013-04-08 2014-10-16 Cowans Kenneth W Air supply concepts to improve efficiency of vcrc engines
EP4678242A3 (en) 2013-04-18 2026-03-18 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
JP6067181B2 (ja) 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
JP6471153B2 (ja) 2013-10-17 2019-02-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルドステロン合成酵素阻害剤としての新規フェニルジヒドロピリジン誘導体
KR20160100408A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제 저해제
HUE039981T2 (hu) 2014-07-24 2019-02-28 Boehringer Ingelheim Int Aldoszteron szintáz inhibitorok
WO2016061161A1 (en) 2014-10-15 2016-04-21 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
WO2016119706A1 (zh) 2015-01-29 2016-08-04 南京明德新药研发股份有限公司 抗肺结核病的硝基咪唑衍生物
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
KR20190084096A (ko) 2016-11-10 2019-07-15 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
CN109053637B (zh) 2018-08-14 2021-03-16 杭州泽旺生物科技有限公司 尺蠖类性信息素及其中间体的合成方法

Also Published As

Publication number Publication date
EP4447961A1 (en) 2024-10-23
US12263157B2 (en) 2025-04-01
AU2022415313A1 (en) 2024-05-02
US20250049763A1 (en) 2025-02-13
US20230181538A1 (en) 2023-06-15
MX2024007335A (es) 2024-06-26
CL2024001470A1 (es) 2024-09-13
TW202339719A (zh) 2023-10-16
KR20240122521A (ko) 2024-08-12
CA3236890A1 (en) 2023-06-22
CN118401241A (zh) 2024-07-26
AR127948A1 (es) 2024-03-13
WO2023114170A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP2025500826A (ja) 慢性腎疾患を処置するためのアルドステロンシンターゼ阻害薬
JP6508544B2 (ja) 腫瘍を治療するための薬用組成物
JP6365993B2 (ja) キノリン誘導体による軟部組織肉腫の治療方法と用途、及び軟部組織肉腫治療するための薬用組成物
CN112839649A (zh) Cxcr4抑制剂组合物以及制备和使用的方法
AU2018308871A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
KR20140107574A (ko) Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
TW201835064A (zh) 苯并噻吩雌激素受體調節劑
KR20140107578A (ko) Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
JP2023529812A (ja) 非小細胞肺癌の治療に使用するためのｅｇｆｒ ｔｋｉ
CN108349900A (zh) 雄激素受体拮抗剂
KR20170036010A (ko) 조합 요법
WO2024033513A1 (en) Compounds for treating cancer
JP2023514794A (ja) ポリａｄｐリボースポリメラーゼ阻害剤の抗コロナウイルス応用
AU2024329573A1 (en) Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure
US10391101B2 (en) Derivatives of 7-fluoro-8-chloro-5H-dibenzo [B,E,] [1,4] diazepine and use thereof
WO2024167904A1 (en) Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor
JP6726138B2 (ja) （３ｓ，３ｓ’）４，４’−ジスルファンジイルビス（３−アミノブタン １−スルホン酸）および第２の抗高血圧剤の組合せ
JP2025510685A (ja) 門脈圧亢進症を処置するための可溶性グアニル酸シクラーゼ活性化薬
JP2023539788A (ja) 口内乾燥症の治療剤
WO2025181153A1 (en) Use of atr inhibitors in combination with pi3k alpha inhibitors
HK40120197A (en) Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers
CA2848724A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
CN118973583A (zh) Tyk2抑制剂及其用途
JP2023549564A (ja) アンドロゲン受容体変異型前立腺がんの治療のためのｅｚｈ２阻害療法
HK40103046A (en) Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251215